AIM ImmunoTech Reports First Quarter Financial Results and P

– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance... | May 15, 2023

Related Keywords

United States , American , Thomask Equels , Jenene Thomas , Christopher Mcaleer , Nancyk Bryan , W Neal Burnette , Facebook , Linkedin , Immunotech Inc , Twitter , Chief Executive Officer , Scientific Advisory Board , Institutional Review Board , Advanced Pancreatic Cancer , Recurrent Ovarian Cancer , Pancreatic Cancer , Financial Highlights , First Quarter , Webcast Details , Scientific Officer Christopher Mcaleer , Tech Conference , Private Securities Litigation Reform Act , Aim Immunotech Inc Stock Exchange , News , Information , Press Release , Ontinued , Execution , Cross , Pipeline , Positions , Rim , O , Chieve , Multiple , Linical , End , Egulatory , Ilestones , Hroughout , Head , Hase , , Ocally Aim Us00901b1052 ,